Sure, I mean, what we’re trying to do is look at the data from the Health Division as a unit rather than go too much into the weeds in terms of the different countries. Certainly, what we just mentioned or Eduardo just mentioned in his remarks, is that of the 20 plus growth in the aggregate, you can decompose it into high single-digit for South America and basically flat for Mexico. And of course, this quarter, we're getting a pretty significant bump from the currency effect, which down the road, we're probably going to see a lot of fluctuations there. But right now, the peso did weaken against most other currencies. And so, you get very, very high same-store sales numbers. So, I wouldn't want to go into any more detail than that. I think that's illustrative of what's happening on the ground in each one of the countries. So, very, very healthy in South America. And in Mexico clearly, we’re facing the challenges of having what is a new brand that begins to go national. You're facing some increased competition in some markets. You're facing the growing pains really of what is still a very fluctuating [ph] operation in Mexico. So, I will say for -- our expectation that I described for 2017, I would again expect South America to contribute not only because it represents 80% of the operation, right, let's remember that that is our Health Division is 80% South America. So, I would again expect Chile and Colombia to grow more than Mexico, not because Mexico from a macro standpoint is not doing well, but because of all the stuff that's going on, as we build our Company and also our continued exposure to the southeast where we are somewhat exposed to Pemex continuing to lay off people and kind of trim itself into a more lean competitor. So, I would say next year, probably looks a lot like this, like 2016, without necessarily the benefit from the currency translation.